Carl Zeiss Meditec/€AFX
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Carl Zeiss Meditec
Carl Zeiss Meditec AG, publicly traded under the ticker symbol AFX, specializes in the healthcare technology sector. Founded in 2002 as a spin-off from Carl Zeiss AG, it provides comprehensive medical solutions for ophthalmology and microsurgery. Operating globally, the company combines its expertise in optics, electronics, and precision engineering to offer innovative products that enhance patient care and clinical outcomes.
Ticker
€AFX
Sector
Primary listing
XETRA
Industry
Health Care Equipment & Supplies
Headquarters
Employees
5,713
ISIN
DE0005313704
AFX Metrics
BasicAdvanced
€5.1B
32.95
€1.77
1.23
€0.60
1.03%
Price and volume
Market cap
€5.1B
Beta
1.23
52-week high
€71.65
52-week low
€44.28
Average daily volume
125K
Dividend rate
€0.60
Financial strength
Current ratio
2.044
Quick ratio
1.056
Long term debt to equity
27.279
Total debt to equity
28.461
Dividend payout ratio (TTM)
33.69%
Interest coverage (TTM)
5.67%
Profitability
EBITDA (TTM)
236.372
Gross margin (TTM)
52.43%
Net profit margin (TTM)
7.19%
Operating margin (TTM)
8.20%
Effective tax rate (TTM)
23.26%
Revenue per employee (TTM)
€380,000
Management effectiveness
Return on assets (TTM)
3.48%
Return on equity (TTM)
7.47%
Valuation
Price to earnings (TTM)
32.954
Price to revenue (TTM)
2.368
Price to book
2.44
Price to tangible book (TTM)
13.04
Price to free cash flow (TTM)
61.864
Free cash flow yield (TTM)
1.62%
Free cash flow per share (TTM)
94.45%
Dividend yield (TTM)
1.03%
Forward dividend yield
1.03%
Growth
Revenue change (TTM)
5.21%
Earnings per share change (TTM)
-39.40%
3-year revenue growth (CAGR)
7.74%
10-year revenue growth (CAGR)
8.65%
3-year earnings per share growth (CAGR)
-15.73%
10-year earnings per share growth (CAGR)
8.25%
3-year dividend per share growth (CAGR)
-12.64%
10-year dividend per share growth (CAGR)
4.14%
What the Analysts think about AFX
Analyst ratings (Buy, Hold, Sell) for Carl Zeiss Meditec stock.
Bulls say / Bears say
The acquisition of DORC contributed €99.9 million to the Ophthalmology Strategic Business Unit, indicating successful expansion into the retinal surgery market. (zeiss.com)
The approval of the VISUMAX® 800 refractive laser system for the Chinese market is expected to drive significant growth in the region. (zeiss.com)
The company has implemented stringent cost control measures, reducing operating expenses below €200 million for the first time in two years, which is expected to strengthen margin recovery. (seat11a.com)
The company experienced a decline in revenue of -1.1% in fiscal year 2023/24, with adjusted EBIT falling to €245.9 million from €362.9 million the previous year, indicating financial struggles. (zeiss.com)
Analysts have issued a 'Sell' rating due to anticipated difficulties in upcoming fiscal years and the necessity for significant restructuring to achieve a more favorable outlook. (markets.businessinsider.com)
The Microsurgery strategic business unit generated revenue of €477.0 million, a decline of -7.0%, mainly due to weak neurosurgery business and investment reluctance in North America. (zeiss.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AFX Financial Performance
Revenues and expenses
AFX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Carl Zeiss Meditec stock?
Carl Zeiss Meditec (AFX) has a market cap of €5.1B as of June 20, 2025.
What is the P/E ratio for Carl Zeiss Meditec stock?
The price to earnings (P/E) ratio for Carl Zeiss Meditec (AFX) stock is 32.95 as of June 20, 2025.
Does Carl Zeiss Meditec stock pay dividends?
Yes, the Carl Zeiss Meditec (AFX) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is €0.6 and the yield is 1.03%. Carl Zeiss Meditec has a payout ratio of 33.69% on a trailing twelve-month basis.
When is the next Carl Zeiss Meditec dividend payment date?
The next Carl Zeiss Meditec (AFX) dividend payment date is unconfirmed.
What is the beta indicator for Carl Zeiss Meditec?
Carl Zeiss Meditec (AFX) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.